• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].

作者信息

Galienne Maxime, Rodrigues Manuel

机构信息

CHU d'Amiens, service d'oncologie radiothérapie, 1, rue du Professeur Christian-Cabrol, 80000 Amiens, France.

PSL Research University, Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75248 Paris cedex 05, France.

出版信息

Bull Cancer. 2021 Jul-Aug;108(7-8):675-676. doi: 10.1016/j.bulcan.2021.04.006. Epub 2021 May 14.

DOI:10.1016/j.bulcan.2021.04.006
PMID:33994164
Abstract
摘要

相似文献

1
[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].[新药获批：多斯塔利单抗——用于晚期微卫星高度不稳定子宫内膜癌的二线治疗]
Bull Cancer. 2021 Jul-Aug;108(7-8):675-676. doi: 10.1016/j.bulcan.2021.04.006. Epub 2021 May 14.
2
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.度伐利尤单抗治疗原发性晚期或复发性子宫内膜癌。
N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.
3
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.度伐利尤单抗治疗复发性或原发性晚期子宫内膜癌。
Future Oncol. 2021 Mar;17(8):877-892. doi: 10.2217/fon-2020-0655. Epub 2020 Nov 30.
4
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis.免疫检查点抑制剂联合治疗晚期子宫内膜癌患者的网络荟萃分析和成本效用分析。
Int J Gynecol Cancer. 2024 Oct 7;34(10):1570-1579. doi: 10.1136/ijgc-2024-005296.
5
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.PD-1抑制剂瑞替凡利单抗在复发的微卫星高度不稳定或错配修复缺陷子宫内膜癌患者中的抗肿瘤活性和安全性：POD1UM-101 I期研究队列H的最终安全性和疗效结果
Gynecol Oncol. 2024 Jul;186:191-198. doi: 10.1016/j.ygyno.2024.05.025. Epub 2024 Jun 1.
6
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.多塔利单抗治疗晚期或复发性 DNA 错配修复缺陷/微卫星不稳定高（dMMR/MSI-H）或 proficient/stable（MMRp/MSS）子宫内膜癌患者的安全性和抗肿瘤活性：GARNET 研究的初步结果，一项 I 期单臂研究。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003777.
7
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.错配修复缺陷、基于下一代测序的微卫星不稳定性和肿瘤突变负担作为预测生物标志物，用于预测晚期子宫内膜癌一线治疗中免疫检查点抑制剂的疗效。
Int J Gynecol Cancer. 2023 Apr 3;33(4):504-513. doi: 10.1136/ijgc-2022-004026.
8
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.多塔利单抗治疗子宫内膜癌的安全性、有效性和生物标志物分析：GARNET 研究的 I 期结果的中期分析。
Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915.
9
[Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer].多斯塔利单抗联合化疗治疗原发性晚期或复发性子宫内膜癌
Bull Cancer. 2024 May;111(5):433-434. doi: 10.1016/j.bulcan.2024.01.007. Epub 2024 Mar 15.
10
Dostarlimab for the treatment of advanced endometrial cancer.多斯塔利单抗用于治疗晚期子宫内膜癌。
Expert Rev Clin Pharmacol. 2022 Jan;15(1):1-9. doi: 10.1080/17512433.2022.2044791. Epub 2022 Feb 22.

引用本文的文献

1
Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.PD-1/PD-L1抑制剂作为单药免疫疗法治疗子宫内膜癌的疗效与安全性：一项系统评价和荟萃分析
Cancers (Basel). 2023 Aug 9;15(16):4032. doi: 10.3390/cancers15164032.
2
F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab.术前使用PD-1抑制剂多斯塔利单抗治疗复发性子宫内膜癌的F-FDG PET/CT
Diagnostics (Basel). 2021 Jul 28;11(8):1353. doi: 10.3390/diagnostics11081353.
3
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
两个检查点的交集：抑制DNA损伤反应检查点能否挽救免疫检查点难治性癌症？
Cancers (Basel). 2021 Jul 8;13(14):3415. doi: 10.3390/cancers13143415.